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Abstract
Aims/hypothesis—Type 2 diabetes is associated with cognitive impairments, but it is unclear 
whether common genetic factors influence both type 2 diabetes risk and cognition.
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Methods—Using data from 1892 Mexican-American individuals from extended pedigrees, 
including 402 with types 2 diabetes, we examined possible pleiotropy between type 2 diabetes and 
cognitive functioning, as measured by a comprehensive neuropsychological test battery.
Results—Negative phenotypic correlations (ρp) were observed between type 2 diabetes and 
measures of attention (Continuous Performance Test [CPT d’]: ρp =−0.143, p=0.001), verbal 
memory (California Verbal Learning Test [CVLT] recall: ρp = −0.111, p=0.004) and face memory 
(Penn Face Memory Test [PFMT]: ρp = −0.127, p=0.002; PFMT Delayed Test: xp = −0.148, 
p=2×10−4), replicating findings of cognitive impairment in type 2 diabetes. Negative genetic 
correlations (ρg) were also observed between type 2 diabetes and measures of attention (CPT d’: 
ρg = −0.401, p=0.001), working memory (digit span backward test: ρg = −0.380, p=0.005), and 
face memory (PFMT: ρg = −0.476, p=2×10−4; PFMT Delayed Test: ρg = −0.376, p=0.005), 
suggesting that the same genetic factors underlying risk for type 2 diabetes also influence poor 
cognitive performance in these domains. Performance in these domains was also associated with 
type 2 diabetes risk using an endophenotype ranking value approach. Specifically, on measures of 
attention (CPT d’: β = −0.219, p=0.005), working memory (digit span backward: β = −0.326, 
p=0.035), and face memory (PFMT: β = −0.171, p=0.023; PFMT Delayed Test: β = −0.215, 
p=0.005), individuals with type 2 diabetes showed the lowest performance, while unaffected/
unrelated individuals showed the highest performance, and those related to an individual with type 
2 diabetes performed at an intermediate level.
Conclusions/interpretation—These findings suggest that cognitive impairment may be a 
useful endophenotype of type 2 diabetes and, therefore, help to elucidate the pathophysiological 
underpinnings of this chronic disease.
Keywords
Cognitive function; Cognitive impairment; Genetic correlation; Genetic overlap; Type 2 diabetes
Introduction
Over 29 million Americans have diabetes and 90–95% of these have type 2 diabetes [1]. If 
current trends continue, as many as one in three Americans are predicted to have diabetes by 
2050 [1, 2], prompting Zimmet and colleagues to claim that type 2 diabetes is an ‘epidemic’ 
with profound societal consequences [3].
From the prospective of pathophysiology, the sevenfold increase in type 2 diabetes 
prevalence over the past 60 years [2] must be due to environmental factors (or the interaction 
of environmental factors with genetic background) since genetic variation on such a short 
timescale is relatively constant. Nevertheless, high concordance rates for type 2 diabetes in 
identical twins [4, 5] and aggregation of type 2 diabetes in families [6, 7] suggest that 
genetic factors play an important role in illness liability. However, despite recent progress in 
delineating the genetic architecture of type 2 diabetes [8], only around 10% of the risk 
attributable to genetic factors has been identified [9]. A potential reason for the slow 
progress in demarcating genomic regions that confer type 2 diabetes risk is that the genetic 
architecture of the illness is highly heterogeneous [10]. One strategy to reduce this 
heterogeneity is the application of allied phenotypes or endophenotypes [11], defined as 
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traits that are genetically related to, but not a symptom of, an illness. The endophenotype 
must show shared genetic aetiology with illness risk, such that the biological mechanisms 
underlying the endophenotype overlap with those that are disrupted in the disease [12]. Yet, 
despite the potential utility of the endophenotype strategy, relatively few studies have 
attempted to identify potential endophenotypes for type 2 diabetes.
While there are many potential medical complications of type 2 diabetes, cognitive 
impairment and dementia are increasingly recognised as clinically important [13]. Indeed, 
individuals with type 2 diabetes have a 1.5 times increased risk for Alzheimer’s disease and 
other dementias [14], with longitudinal studies consistently reporting that type 2 diabetes in 
midlife is associated with increased risk of dementia in later life [14]. A recent meta-analysis 
of 2.3 million individuals, including more than 100,000 with dementia, found a 60% 
increased risk of any dementia in men and women with type 2 diabetes (women, pooled 
relative risk: 1.62; men, pooled relative risk: 1.58) [15]. Moreover, individuals with type 2 
diabetes have modest, yet reliable, cognitive decrements when compared with individuals 
without type 2 diabetes [16, 17]. For example, meta-analyses report small to moderate 
impairments on measures of processing speed (Cohen’s d −0.43 to −0.22 [18–20]), verbal 
declarative memory (d = −0.51 to −0.27 [18, 20]), visual declarative memory (d =−0.26 [18, 
20]), executive functioning (d = −0.52 to −0.25 [18–20]) and motor functioning (d = −0.36 
[18]) in individuals with type 2 diabetes. Cognitive impairments are also present in 
individuals with recent-onset type 2 diabetes [21], adolescents who later develop diabetes 
[22] and in individuals with impaired glucose tolerance [23]. Thus, at least part of the 
cognitive impairment associated with type 2 diabetes appears to preceed onset and may be 
related to risk for the illness.
Unlike other common sequelae of type 2 diabetes (e.g. retinopathy or peripheral 
neuropathy), cognitive impairments are only weakly associated with peripheral blood 
glucose levels or glucose regulation [24], suggesting that these impairments are not entirely 
due to current metabolic dysfunction (e.g. insulin resistance). Poor cognitive functioning 
also appears to be a risk factor for metabolic dysregulation [13], such as severe 
hypoglycaemic episodes [25], suggesting a bidirectional association between cognition and 
type 2 diabetes. Moreover, in a systematic review and synthesis of the literature, Biessels 
and colleagues [25] noted that effect sizes of cognitive impairment in type 2 diabetes are 
consistent across the lifespan and similar to those reported in individuals with impaired 
glucose tolerance [23], suggesting minimal influence of illness duration and/or age. Given 
evidence that cognitive impairments show relatively little association with clinical state, 
exist prior to illness onset and show minimal progression [13, 14], it is possible that at least 
some of the cognitive complications of type 2 diabetes reflect subtle biological changes 
associated with liability for type 2 diabetes. In other words, cognitive impairment may be an 
endophenotype of type 2 diabetes.
Using data from a large sample of Mexican-American individuals from extended pedigrees, 
we sought to find evidence for possible pleiotropy between cognitive functioning and type 2 
diabetes, such that the genetic factors influencing these two traits overlap. Specifically, our 
aims were to: (1) estimate the heritability of type 2 diabetes and cognitive functioning in this 
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sample; (2) quantify the genetic correlation between these two traits; and (3) test for the 
effect of duration of type 2 diabetes on cognitive functioning.
Methods
Sample
Participants were from the Genetics of Brain Structure and Function (GOBS) study [26, 
27],which is part of the San Antonio Family Heart Study (SAFH). Cognitive data and data 
on type 2 diabetes status were available for 1892 participants from 96 pedigrees (average 
[mean] family size, 19.2; range, 2–189). The sample was 60.4% female and had a mean age 
of 49.9 years (SD, 15.6; range, 18–97). GOBS data collection occurred between 2006 and 
2016. Of the 1892 individuals, 402 received a type 2 diabetes diagnosis (see below), 1247 
were related to an affected individual and 243 were unrelated to an affected individual (Table 
1).
All participants were randomly selected from the community with the constraints that they 
were of Mexican-American ancestry, part of a large family, and lived in the San Antonio 
(TX, USA) region. All participants provided written informed consent. The institutional 
review board (IRB) at the University of Texas Science Center at San Antonio approved the 
study.
Neurocognitive assessment
Participants completed a 90 min neuropsychological test battery consisting of standard and 
computerised measures [28], including measures of attention, executive processing, working 
memory, declarative memory, language processing, intelligence and emotional processing. 
The vocabulary and matrix reasoning subtests of the Wechsler Abbreviated Scale of 
Intelligence (WASI) [29] provided an estimate of intelligence quotient (IQ). Participants 
were tested in their choice of language; 132 (7%) participants were tested in Spanish and the 
remainder were tested in English.
Type 2 diabetes diagnosis
Participants were classified as having type 2 diabetes if they had a fasting glucose 
concentration ≥7.0 mmol/l and/or a 2 h glucose level ≥11.1 mmol/l after OGTT. Participants 
who did not meet these criteria, but reported current treatment with oral glucose-lowering 
agents or insulin, and a history of diabetes, were also classified as having type 2 diabetes.
Quantitative genetic analysis
Univariate models—All genetic analyses were performed using the Sequential 
Oligogenetic Linkage Analysis Routines (SOLAR) software [30]. SOLAR implements a 
maximum likelihood variance decomposition to determine the proportion of variation in a 
phenotype due to genetic and environmental influences by modelling the covariance 
amongst family members as a function of genetic proximity. This approach can handle 
pedigrees of arbitrary size and complexity and, thus, is optimally efficient with regard to 
extracting maximal genetic information. The simplest such decomposition is one where the 
additive genetic contribution of a trait is indexed by the heritability (h2). All cognitive 
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measures and type 2 diabetes underwent univariate decomposition analysis to ensure they 
were significantly heritable. Raw continuous traits were subjected to rank-based inverse-
normal transformation to ensure that they were normally distributed. Residualised traits were 
then generated by entering age, age2 and sex, and their interactions, as well as testing 
language and years of education, as fixed-effect covariates in all models. These residualised 
traits were used in all subsequent analyses. To control for multiple testing, the false 
discovery rate (FDR) was set at 5% in all genetic and statistical models [31].
Bivariate models—Bivariate polygenic models were used to decompose the phenotypic 
covariance between each neurocognitive measure and type 2 diabetes status into genetic and 
environmental constituents to determine the extent by which they were influenced by shared 
genetic effects. Specifically, bivariate polygenic analyses were performed to estimate 
phenotypic (ρp), genetic (ρg) and environmental (ρe) correlations, where: ρp = ρg√(h2eh2i) + 
ρe√[(1−h2e)(1−h2i)], where h2e is the heritability of the endophenotype and h2i is the 
heritability of the illness. The significance of these correlations was tested by comparing the 
log likelihood for two restricted models (with ρp, ρg or ρe constrained to equal 0) against the 
log likelihood for the model in which these parameters were estimated. A significant 
phenotypic correlation is evidence for a phenotypic association (i.e. including both genetic 
and environmental influences) between neurocognitive measures and a type 2 diabetes 
diagnosis. A significant environmental correlation is evidence for a non-genetic factor 
jointly influencing both traits. A significant genetic correlation is evidence for pleiotropy 
suggesting that a gene or set of genes jointly influences both phenotypes. It is worth noting 
that there are multiple possible interpretations of genetic correlations. While the same 
genetic variants may contribute both to type 2 diabetes risk and cognitive functioning 
(horizontal pleiotropy), genetic variants related to type 2 diabetes risk may also have indirect 
effects on cognition (vertical pleiotropy) [32]. Nevertheless, the mechanisms underlying the 
observed genetic correlations between type 2 diabetes and cognitive impairment do not deter 
from the potential use of cognitive functioning as an endophenotype for type 2 diabetes. We 
also used bivariate models to decompose the phenotypic covariance between each 
neurocognitive measure and BMI, as well as between each neurocognitive measure and 
waist circumference.
Endophenotype Ranking Values—Parameters from these bivariate models were used 
to calculate endophenotype ranking values (ERVs). The ERV objectively prioritises potential 
endophenotypes for use in molecular genetics analyses [33]. The ERV represents the 
standardised genetic covariance between an endophenotype and an illness, defined as ERV = 
√(h2eh2i)|ρg|, where h2e is the heritability of the endophenotype, h2i is the heritability of the 
illness and ρg is their genetic correlation. The ERV provides a measure between 0 and 1, 
with higher values indicating a stronger combination of genetic signal and relationship to 
disease.
Mean-based ERV calculation—The mean-based ERV (mERV) is an extension of the 
ERV. For details on the derivation of the mERV, see Glahn et al [34]. Briefly, the mERV 
leverages the many coefficients of relationship that exist in extended-pedigree data. The 
coefficient of relationship refers to the average (mean) number of alleles held in common 
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between individuals. For example, first-degree relatives (e.g. full siblings or parents) share, 
on average, 50% of their alleles, whilst second-degree relatives (e.g. grandparents or aunts/
uncles) share 25%, third-degree relatives (e.g. great-grandparents or great aunts/uncles) 
share 12.5% and so on. Thus, it is possible, given an individual with a disease, to index all 
other pedigree members by their degree of relatedness to that individual. For non-affected 
individuals with more than one relative with type 2 diabetes, the highest degree of 
relatedness is used. This scalar can then be used to perform a fixed-effect single-degree-of-
freedom test within the univariate variance components analysis outlined above, providing 
an estimate of the standardised genetic covariance between the potential endophenotype and 
illness risk. The mERV can then be used in the same way as the ERV to rank potential 
endophenotypes by their degree of standardised genetic overlap with illness risk. In the 
present paper, the mERV was applied to type 2 diabetes and all neurocognitive measures 
with statistically significant genetic correlations.
Statistical analyses
We used ANOVA models, implemented in the statistical programming language R [35], to 
test for the effect of duration of type 2 diabetes on neurocognitive functioning. Participants 
with type 2 diabetes were categorised into two illness duration groups: (1) duration of less 
than 10 years; and (2) duration of 10 or more years. Neurocognitive scores were residualised 
in SOLAR for sex and testing language, then subsequently for sex, testing language and age. 
Finally, the three groups (unaffected, duration <10 years, duration ≥10 years) were matched 
by age using the ‘MatchIt’ package in R.
We also examined the effect of duration of type 2 diabetes on neurocognitive functioning 
using linear regression models. Duration in years was modelled onto cognitive functioning, 
both as linear and quadratic functions, the latter to account for potential nonlinearity in the 
association between type 2 diabetes duration and cognitive functioning.
Results
Evidence for pleiotropy between type 2 diabetes and neurocognition
Table 2 shows results of univariate and bivariate genetic analyses of type 2 diabetes on 
neurocognitive functioning. All neurocognitive measures were significantly heritable (h2 
range, 0.17–0.59), as was type 2 diabetes (h =0.59; p=6×10−14). Significant phenotypic 
correlations were observed between type 2 diabetes and measures of attention (Continuous 
Performance Test [CPT d’]: ρp = −0.143, p=0.001), verbal memory (California Verbal 
Learning Test [CVLT] recall: ρp = −0.111, p=0.004), and face memory (Penn Face Memory 
Test [PFMT]: ρp = −0.127, p=0.002; PFMT Delayed Test: ρp = −0.148, p=2×10−4). These 
statistically significant phenotypic correlations were in line with standardised mean 
difference effect sizes (Fig. 1). Significant genetic correlations were observed between type 
2 diabetes and CPT d’ (ρg = −0.401, p=0.001), digit span backward (ρg = −0.380, p=0.005), 
PFMT (ρg = −0.476, p=2×10−4) and PFMT Delayed Test (ρg = −0.376, p=0.005), suggesting 
overlap between the genetic factors influencing type 2 diabetes and performance on 
measures of attention, working memory and face memory, respectively. Figure 2 shows 
results of mERV analyses. Standardised genetic covariances were statistically significant for 
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all cognitive measures: CPT d’ (β = −0.219, p=0.005), digit span backward (β = −0.326, 
p=0.035), PFMT (β = −0.171, p=0.023) and PFMT Delayed Test (β = −0.215, p=0.005). 
However, the effect of relatedness on cognition differed between these measures; for CPT d’, 
individuals with type 2 diabetes had the lowest scores, followed by their first-degree 
relatives and then their second- to sixth- degree relatives, whilst unaffected/unrelated 
individuals scored the highest. For the digit span backward, individuals with type 2 diabetes 
and their first-degree relatives had the lowest scores, followed by their second- to sixth- 
degree relatives, and unaffected/unrelated individuals scored the highest. For PFMT and 
PFMT Delayed Test, individuals with type 2 diabetes had the lowest scores, unaffected/
unrelated individuals had the highest scores, and those related to an individual with type 2 
diabetes had intermediate scores.
No evidence for pleiotropy between BMI or waist circumference and neurocognition
Bivariate genetic analyses of BMI and waist circumference on cognitive functioning are 
shown in the electronic supplementary material (ESM) Table 1 and Table 2, respectively. 
Phenotypic, environmental and genetic correlations did not reach significance for any 
neurocognitive measure after correction for multiple testing, except for the phenotypic 
correlation between CPT d’ and waist circumference (ρp = −0.084; ESM Table 2).
Deleterious effects of illness duration on neurocognition are confounded by age
Demographic characteristics of the unmatched and matched samples grouped by duration of 
type 2 diabetes (unaffected, duration <10 years, duration ≥10 years) are shown in ESM Table 
3. ESM Fig. 1 shows age distributions for the age-matched groups. In the unmatched 
sample, the groups separated by type 2 diabetes duration differed significantly by age 
(p<0.001); in the matched sample, there was no statistically significant difference in age 
(p=0.714; ESM Table 3).
Analysis of illness duration group status on neurocognitive functioning are shown in Fig. 3 
and ESM Table 4. When adjusting for sex, the duration <10 years group had lower cognitive 
scores than the unaffected individuals for 13 out of the 19 cognitive measures, while the 
duration ≥10 years group showed lower scores than the unaffected individuals for 16 out of 
the 19 measures (ESM Table 4). Moreover, the duration ≥10 years group showed lower 
scores than the duration <10 years group for digit symbol substitution (ß = −0.24, p=0.017), 
Trail-Making A (ß = −0.36, p=0.001), digit span forward (ß = −0.32, p=0.003), Trail-
Making B (ß = −0.24, p=0.041), CVLT recall (ß = −0.26, p=0.018) and emotion recognition 
(ß=−0.28, p=0.013). Matching the groups by age attenuated most of these group differences, 
with the duration <10 years group performing worse than the unaffected individuals for CPT 
d’ (ß = −0.30, p=0.006), PFMT (ß = −0.27, p=0.015) and PFMT Delayed Test (ß = −0.27, 
p=0.014), the duration ≥10 years group performing worse than the unaffected individuals for 
CPT d’ (ß = −0.26, p=0.026), digit span forward (ß = −0.23 p=0.047), CVLT recall (ß = 
−0.23, p=0.049) and PFMT Delayed Test (ß = −0.23, p=0.049), and the duration ≥10 years 
group performing worse than the duration <10 years group for digit span forward (ß = −0.34, 
p=0.010). Adjusting additionally for age further attenuated these group differences, with the 
duration <10 years group performing worse than the unaffected individuals for PFMT (ß = 
−0.18, p=0.042) and PFMT Delayed Test (ß = −0.22, p=0.009), the duration ≥10 years group 
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performing worse than the unaffected individuals for CVLT recall (ß = −0.20, p=0.011), and 
no statistically significant differences between the duration ≥10 years and duration <10 years 
groups.
Analyses of illness duration on cognitive functioning, with illness duration years as linear 
and quadratic functions, are shown in ESM Table 5 and ESM Table 6, respectively. Results 
were similar to above, with a significant effect of duration (linear function) on digit symbol 
substitution (ß = −0.019, p=0.001), Trail-Making A (ß = −0.023, p=0.002), digit span 
forward (ß = −0.016, p=0.021), digit span backward (ß = −0.013, p=0.046), letter number 
sequencing (ß = −0.014, p=0.021), Trail-Making B (ß = −0.021, p=0.006), CVLT learning (ß 
= −0.014, p=0.023), CVLT recall (ß = −0.014, p=0.031) and emotion recognition (ß = − 
0.015, p=0.021) (ESM Table 5 and ESM Fig. 2). A significant effect of duration as a 
quadratic function, was also seen on digit symbol substitution (ß = −0.0006, p=0.001), Trail-
Making A (ß = −0.0007, p=0.014), digit span forward (ß = −0.0005, p=0.034), letter number 
sequencing (ß = −0.0005, p=0.011), Trail-Making B (ß = −0.0007, p=0.011), CVLT learning 
(ß = −0.0005, p=0.014), and emotion recognition (ß = − 0.0005, p=0.043) (ESM Table 6 and 
ESM Fig. 3). No statistically significant effect of illness duration was seen when groups 
were matched for age, except for digit span forward (ß = −0.019, p=0.009 for effect of 
duration as a linear function [ESM Table 5]; ß = −0.0005, p=0.032 for effect of duration as a 
quadratic function [ESM Table 6]). There were no statistically significant effects of illness 
duration after further adjustment for age.
Discussion
Using a large sample of Mexican-American individuals from extended pedigrees, we 
established evidence for pleiotropy between cognitive impairment and type 2 diabetes. 
Significant genetic correlations were observed between type 2 diabetes and measures of 
attention, working memory and face memory, suggesting genetic overlap between type 2 
diabetes and these cognitive domains. Moreover, significant genetic correlations were not 
observed between either BMI or waist circumference and cognitive performance, suggesting 
that the genetic overlap between type 2 diabetes and cognitive functioning is specific to the 
illness and not seen with general obesity factors. Finally, although there was an effect of 
duration of type 2 diabetes on magnitude of cognitive impairment, with individuals with a 
longer duration of illness showing larger impairments than individuals with a shorter 
duration of illness, these group differences were confounded by age. Our findings add to 
current knowledge about the pathophysiology of type 2 diabetes in several important ways.
First, the finding of pleiotropy between cognitive functioning and type 2 diabetes may be an 
important step forward in delineating the genetic underpinnings of type 2 diabetes, which 
affects an exponentially increasing number of individuals worldwide. While there has been 
progress in delineating the genetic architecture of type 2 diabetes [8], some argue that the 
illness remains ‘a geneticist’s nightmare’ [9]. One strategy for identifying risk genes for type 
2 diabetes is the application of endophenotypes [11, 36], i.e. traits that are genetically related 
to the illness. However, while there is strong evidence to suggest that individuals with type 2 
diabetes show cognitive impairments, few studies have sought to establish whether these 
impairments are genetically correlated with the illness. Our finding of genetic overlap 
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between type 2 diabetes and measures of memory, working memory and attention is in line 
with evidence that the most consistent impairments in individuals with type 2 diabetes are in 
the domains of memory and executive function [18–20]. Moreover, this finding provides 
evidence for one of the principle criteria of endophenotypes: that the same genes that convey 
risk for the illness also influence the endophenotype [36]. Similarly, analyses of data from 
the UK Biobank and 24 international genome-wide association studies (GWAS) consortia 
showed that higher polygenic risk for type 2 diabetes was associated with decreased 
likelihood of obtaining a college degree [37]. However, a higher polygenic risk score (PRS) 
for type 2 diabetes was not associated with verbal reasoning, reaction time or memory in this 
sample [37], and no significant genetic correlations were reported between type 2 diabetes 
and any of the cognitive or education phenotypes when using linkage disequilibrium score 
regression (LDSC) [37]. Moreover, Mendelian randomisation (MR) analyses in the same 
sample provided no evidence for a causal association between type 2 diabetes and cognitive 
ability or educational attainment [38]. However, the methods used in the UK Biobank (PRS, 
LDSC and MR) primarily capture common genetic variance, while the genetic correlations 
observed in our study may be driven, at least in part, by rare genetic variants. In an ageing 
cohort, genetic risk of type 2 diabetes was positively associated with fluid intelligence, but 
no association was detected between type 2 diabetes PRS and verbal intelligence, memory or 
processing speed [39]. Thus, while our findings suggest that cognitive impairment may be a 
useful endophenotype of type 2 diabetes, future studies are needed to disentangle the genetic 
overlap between these traits at different ages, as well as across different cognitive domains. 
It is also worth noting that there are multiple possible interpretations of genetic correlations. 
While the same genetic variants may contribute both to type 2 diabetes risk and cognitive 
functioning, genetic variants related to type 2 diabetes risk may also have indirect effects on 
cognition, and genetic variants related to cognition may even have indirect effects on type 2 
diabetes [32]. Nevertheless, the mechanisms underlying the observed genetic correlations 
between type 2 diabetes and cognitive impairment do not deter from the potential utility of 
cognitive functioning as an endophenotype for type 2 diabetes.
Second, we did not find evidence for a genetic association between cognitive function and 
either BMI or waist circumference. Previous evidence from twin and molecular genetic 
models indicate inconsistent findings regarding the genetic association between BMI and 
cognitive functioning, with reports of medium [40], small [41] and null [42] genetic 
correlations between the two traits. Even at the phenotypic level, the association between 
BMI and cognitive functioning is unclear, with reports of no association [43], cognitive 
impairment [44, 45] and even improved cognitive performance [46, 47] with higher BMI. 
We found null to small phenotypic and genetic correlations between neurocognition and 
both BMI and waist circumference, and none of these reached statistical significance after 
correction for multiple testing. Thus, any association between obesity indices and cognitive 
impairment may be due to environmental, rather than genetic, risk factors. Alternatively, 
genetic risk factors may interact with environmental changes throughout the life course, such 
that obesity-related pathology leading to cognitive impairment and/or decline may develop 
gradually over the course of many years [48]. Future studies are needed to determine 
whether this potential association between obesity indices and cognitive performance is 
moderated by age.
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Finally, we found greater cognitive impairment in individuals with a longer duration of type 
2 diabetes, but also that this group difference was attenuated when adjusting for age. Since 
age increases with duration of type 2 diabetes, adjusting for age undoubtedly attenuates part 
of the effect of duration on cognitive functioning. Nevertheless, this finding is in line with 
evidence that the magnitude of cognitive impairment associated with type 2 diabetes remains 
relatively stable throughout the lifespan [25]. Similarly, cognitive impairments are already 
present in individuals with recent-onset type 2 diabetes [21] and even in adolescents who 
later develop diabetes [22]. Moreover, a negligible effect of illness duration on cognition 
aligns with the finding of genetic overlap between type 2 diabetes and cognitive impairment, 
as well as the notion of a bidirectional relationship between these traits [13]. However, there 
have also been reports of an association between duration of type 2 diabetes and magnitude 
of cognitive dysfunction [49, 50]. Future longitudinal studies, which include individuals 
throughout premorbid and post-onset stages of type 2 diabetes, as well as repeating cognitive 
assessments, are needed to fully disentangle the complex mechanisms underlying the 
relationship between type 2 diabetes and poor cognitive outcomes. Moreover, future studies 
that use additional measures, such as blood glucose level and family history of type 2 
diabetes, to examine whether some portion of the cognitive impairment associated with type 
2 diabetes arises as a consequence of the illness, may also help elucidate these mechanisms.
This study has some limitations. First, due to the cross-sectional nature of this study, it is not 
possible to draw inferences about timing. While we found evidence for pleiotropy between 
type 2 diabetes and cognitive impairment, it remains unclear how these overlapping genetic 
factors might interact with other genetic and environmental risk factors over the lifecourse. 
Future longitudinal studies will help elucidate the complex mechanisms underlying risk for 
both type 2 diabetes and cognitive impairment, as well as potential developmental periods 
for optimal intervention and prevention. Second, the aim of this study was to examine 
pleiotropy between type 2 diabetes and cognitive impairment, but other potential 
explanations for the association between type 2 diabetes and cognitive impairment warrant 
further examination. As outlined above, future studies that are able to examine whether some 
portion of the cognitive impairment associated with type 2 diabetes arises due to the illness, 
or even whether some portion of type 2 diabetes risk is consequential to poor cognitive 
functioning, may yield interesting results.
Using a large sample of Mexican-American individuals from extended pedigrees, we 
established evidence for pleiotropy between impairment on measures of attention, working 
memory and memory, and type 2 diabetes. Thus, cognitive impairment may be a useful 
endophenotype of type 2 diabetes and may help elucidate the pathophysiological 
underpinnings of this chronic illness, which affects an large number of individuals 
worldwide. Future longitudinal studies will help disentangle these pathophysiological 
mechanisms over the life course in order to inform treatment strategies and intervention 
efforts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is already known about this subject?
• Type 2 diabetes has been associated with cognitive impairments
• Evidence suggests that these impairments are not sequelae of the illness
• Common genetic factors may influence both type 2 diabetes risk and 
cognitive dysfunction
What is the key question?
• Do the same genetic factors that influence type 2 diabetes risk also influence 
poor cognition?
What are the new findings?
• Negative genetic correlations between type 2 diabetes and performance on 
measures of attention, working memory and face memory suggest genetic 
overlap
• Cognitive performance was lowest in individuals with type 2 diabetes, highest 
in unaffected/unrelated individuals and intermediate in those related to an 
individual with type 2 diabetes
How might this impact on clinical practice in the foreseeable future?
• Cognitive impairment may be a useful endophenotype of type 2 diabetes and 
could help elucidate the pathophysiological underpinnings of this disease, 
eventually leading to improved detection and treatment
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Standardised effect sizes and 95% CIs for all residualised cognitive measures comparing 
individuals with type 2 diabetes with individuals without (control data from unaffected 
individuals set at 0 for all measures). IQ, intelligence quotient; PCET, Penn Conditional 
Exclusion Test
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mERV analysis of cognitive measures with statistically significant genetic correlations, 
plotted by degree of relatedness. (a) CPT d’: β = −0.219, p=0.005; (b) digit span backward: 
β = −0.326, p=0.035; (c) PFMT: β = −0.171, p=0.023; (d) PFMT Delayed Test: β = −0.215, 
p=0.005
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Means and SE of cognitive measures by illness duration, (a) adjusting for sex, (b) adjusting 
for sex and matched for age or (c) adjusting for sex, age, age2, age×sex, age2×sex. IQ, 
intelligence quotient; PCET, Penn Conditional Exclusion Test
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Table 1
Basic demographics of the sample by degree of relatedness to an individual with type 2 diabetes
Degree of relatedness n Age, mean (SD) Sex, % female
Affected 402 54.8 (12.6) 59.6
First degree 561 41.2 (13.4) 63.3
Second degree 337 34.3 (14.9) 57.0
Third degree 222 35.9 (12.7) 57.7
Fourth degree 105 29.4 (9.6) 61.0
Fifth degree 21 24.4 (8.3) 47.6
Sixth degree 1 19 100.0
Unrelated 243 45.5 (15.2) 63.0













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diabetologia. Author manuscript; available in PMC 2021 May 01.
